Iran Press/Iran News: Iranian researchers have succeeded in producing a medicinal drug for treatment of Thalassemia, an inherited blood disorder characterized by abnormal haemoglobin production.
For the first time Iranian biotechnology and nano-researchers have succeeded in producing 'Nanojade', a medicine which gets rid of excess iron in the human body, Iran Press reported.
'Nanojade' is produced by 'Nano Hayat Darou', an Iranian biotechnology firm which produces pharmaceutical medicines and specialises in nanomedicine.
'Nanojade' can be eaten in doses of 90, 180 or 360 milligrams by patients suffering from Thalassemia.
People with Thalassemia can get an overload of iron in their bodies, either from the disease itself or from frequent blood transfusions. Too much iron can result in damage to the heart, liver, and endocrine system, which includes glands that produce hormones that regulate processes throughout the body. The damage is characterized by excessive deposits of iron. Without adequate iron chelation therapy, almost all patients with beta-Thalassemia accumulate potentially fatal iron levels.
Dr. Hassan AbolGhassemi, the head of 'Society for Children suffering from Blood Cancer', commenting on the new drug 'Nanojade', said: "This new medicine will certainly help improve the lives of over 19000 Thalassemia patients living in Iran. Previously the drug had to be imported from abroad and it was very expensive, but now, the Iranian-made version of the drug is much cheaper and much easier to use for the patients." 211/103
Read more:
Sales of Iran's Nanotech products soar
The role of Iranian social security organization in exporting medicine
First International Nano Technology Olympiad held in Iran
